Cheryl L Rowe-Rendleman Selected Research

propan-2-yl 4- (6- (4- (2,5- difluorophenoxy)- 3- hydroxybut- 1- en- 1- yl)- 7- hydroxyoctahydro- 2H- cyclopenta(b)oxepin- 3- yl)butanoate

10/2016	Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.
12/2015	A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cheryl L Rowe-Rendleman Research Topics

Disease

2	Open-Angle Glaucoma (Glaucoma, Open Angle) 10/2016 - 12/2015
2	Ocular Hypertension (Glaucoma, Suspect) 10/2016 - 12/2015
1	Optic Nerve Diseases (Optic Neuropathy) 01/2017
1	Glaucoma 01/2017
1	Retinal Diseases 04/2011
1	Neoplasms (Cancer) 04/2011

Drug/Important Bio-Agent (IBA)

2	propan-2-yl 4- (6- (4- (2,5- difluorophenoxy)- 3- hydroxybut- 1- en- 1- yl)- 7- hydroxyoctahydro- 2H- cyclopenta(b)oxepin- 3- yl)butanoateIBA 10/2016 - 12/2015
1	Retinaldehyde (Retinal)IBA 01/2017
1	ProstaglandinsIBA 12/2015
1	prostaglandin E3 (PGE3)IBA 12/2015
1	prostaglandin F2alpha receptorIBA 12/2015
1	Biomarkers (Surrogate Marker)IBA 04/2011
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2011

Therapy/Procedure

2	Therapeutics 01/2017 - 12/2015
1	Drug Therapy (Chemotherapy) 04/2011